IT202100009926A1 - Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4 - Google Patents

Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4 Download PDF

Info

Publication number
IT202100009926A1
IT202100009926A1 IT102021000009926A IT202100009926A IT202100009926A1 IT 202100009926 A1 IT202100009926 A1 IT 202100009926A1 IT 102021000009926 A IT102021000009926 A IT 102021000009926A IT 202100009926 A IT202100009926 A IT 202100009926A IT 202100009926 A1 IT202100009926 A1 IT 202100009926A1
Authority
IT
Italy
Prior art keywords
combination
ctla4
treatment
itf3756
day
Prior art date
Application number
IT102021000009926A
Other languages
English (en)
Italian (it)
Inventor
Gianluca Fossati
Flavio Leoni
Pietro Samuele Pozzi
Elisabetta Galbiati
Christian Steinkuhler
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Priority to IT102021000009926A priority Critical patent/IT202100009926A1/it
Priority to TW111111338A priority patent/TW202308609A/zh
Priority to ARP220100959A priority patent/AR125356A1/es
Priority to BR112023021125A priority patent/BR112023021125A2/pt
Priority to US18/555,103 priority patent/US20240207228A1/en
Priority to MX2023012030A priority patent/MX2023012030A/es
Priority to JP2023564130A priority patent/JP2024515100A/ja
Priority to AU2022262199A priority patent/AU2022262199A1/en
Priority to CN202280027381.5A priority patent/CN117177745A/zh
Priority to CA3213275A priority patent/CA3213275A1/en
Priority to PE2023002749A priority patent/PE20242078A1/es
Priority to KR1020237039421A priority patent/KR20230172001A/ko
Priority to IL307649A priority patent/IL307649A/en
Priority to PCT/EP2022/060287 priority patent/WO2022223543A1/en
Priority to EP22723425.9A priority patent/EP4326259A1/en
Publication of IT202100009926A1 publication Critical patent/IT202100009926A1/it
Priority to CL2023002894A priority patent/CL2023002894A1/es
Priority to CONC2023/0013780A priority patent/CO2023013780A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IT102021000009926A 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4 IT202100009926A1 (it)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
TW111111338A TW202308609A (zh) 2021-04-20 2022-03-25 包含特定hdac6抑制劑和至少一種ctla4檢查點抑制劑之組合
ARP220100959A AR125356A1 (es) 2021-04-20 2022-04-18 Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4
AU2022262199A AU2022262199A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor
PE2023002749A PE20242078A1 (es) 2021-04-20 2022-04-19 Una combinacion que comprende un inhibidor de hdac6 especifico y al menos un inhibidor del punto de control de ctla4
MX2023012030A MX2023012030A (es) 2021-04-20 2022-04-19 Combinacion que comprende un inhibidor especifico de histona desacetilasa 6 (hdac6) y al menos un inhibidor del punto de control del antigeno 4 del linfocito t citotoxico (ctla4).
JP2023564130A JP2024515100A (ja) 2021-04-20 2022-04-19 特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ
BR112023021125A BR112023021125A2 (pt) 2021-04-20 2022-04-19 Combinação compreendendo um inibidor específico de hdac6 e pelo menos um inibidor do ponto de verificação de ctla4
CN202280027381.5A CN117177745A (zh) 2021-04-20 2022-04-19 包含特定hdac6抑制剂和至少一种ctla4检查点抑制剂的组合
CA3213275A CA3213275A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor
US18/555,103 US20240207228A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor
KR1020237039421A KR20230172001A (ko) 2021-04-20 2022-04-19 특이적 hdac6 억제제와 적어도 하나의 ctla4 체크포인트 억제제를 포함하는 조합물
IL307649A IL307649A (en) 2021-04-20 2022-04-19 A combination that includes a specific HDAC6 inhibitor and at least one CTLA4 Checkpoint inhibitor
PCT/EP2022/060287 WO2022223543A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor
EP22723425.9A EP4326259A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor
CL2023002894A CL2023002894A1 (es) 2021-04-20 2023-09-28 Combinación de un inhibidor de hdac6 y un inhibidor del punto de control de ctla4
CONC2023/0013780A CO2023013780A2 (es) 2021-04-20 2023-10-19 Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4

Publications (1)

Publication Number Publication Date
IT202100009926A1 true IT202100009926A1 (it) 2022-10-20

Family

ID=76808052

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4

Country Status (17)

Country Link
US (1) US20240207228A1 (https=)
EP (1) EP4326259A1 (https=)
JP (1) JP2024515100A (https=)
KR (1) KR20230172001A (https=)
CN (1) CN117177745A (https=)
AR (1) AR125356A1 (https=)
AU (1) AU2022262199A1 (https=)
BR (1) BR112023021125A2 (https=)
CA (1) CA3213275A1 (https=)
CL (1) CL2023002894A1 (https=)
CO (1) CO2023013780A2 (https=)
IL (1) IL307649A (https=)
IT (1) IT202100009926A1 (https=)
MX (1) MX2023012030A (https=)
PE (1) PE20242078A1 (https=)
TW (1) TW202308609A (https=)
WO (1) WO2022223543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119424649A (zh) * 2024-02-29 2025-02-14 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189340A1 (en) 2017-04-14 2018-10-18 Italfarmaco S.P.A. Selective hdac6 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018008346A (es) * 2016-01-11 2019-07-04 Turnstone Lp Terapia de combinación de virus oncológico e inhibidor de punto de control.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189340A1 (en) 2017-04-14 2018-10-18 Italfarmaco S.P.A. Selective hdac6 inhibitors

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 2009
ALDANA-MASANGKAY ET AL., J. BIOMED. BIOTECHNOL., vol. 2011, 2011, pages 875824
ANSARI ET AL., THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, 2003, pages 63 - 69
DOMPIERRE ET AL., J. NEUROSCI., vol. 27, no. 13, 2007, pages 3571 - 3583
FISKUS ET AL., BLOOD, vol. 112, no. 7, 2008, pages 2896 - 2905
HIDESHIMA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, no. 24, 2005, pages 8567 - 8572
J. MED. CHEM., vol. 55, 2012, pages 639 - 651
JENSEN M.M. ET AL., BMC MEDICAL IMAGING, vol. 8, no. 16, 2008, pages 127 - 133
KANG JH ET AL., TRENDS IN IMMUNOLOGY, vol. 42, 2021, pages 293
KAWAGUCHI ET AL., CELL, vol. 115, no. 6, 2003, pages 727 - 738
KEREMU ET AL., CANCER CHEMOTHER PHARMACOL., vol. 83, no. 2, February 2019 (2019-02-01), pages 255 - 264
KNOX ET AL., SCI REP., vol. 9, no. 1, 16 April 2019 (2019-04-16), pages 6136
KORMAN A ET AL: "TUMOR IMMUNOTHERAPY: PRECLINICAL AND CLINICAL ACTIVITY OF ANTI-CTLA4 ANTIBODIES", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 6, no. 6, 1 January 2005 (2005-01-01), pages 582 - 591, XP009062509, ISSN: 1472-4472 *
LARKIN J ET AL., N ENGL J MED, vol. 381, 2019, pages 16
LIENLAF ET AL., MOL ONCOL, vol. 10, no. 5, May 2016 (2016-05-01), pages 735 - 750
MOL. CELL. BIOL., vol. 31, no. 10, 2011, pages 2066 - 2078
OUTERIO ET AL., SCIENCE, vol. 317, no. 5837, 2007, pages 516 - 519
PEARSON ET AL., JOURNAL OF AUTOIMMUNITY, vol. 66, 2016, pages 76 - 88
RAPTOPOULOU ET AL., ARTHRITIS & RHEUMATISM, vol. 62, 2010, pages 1870 - 1880
RAY ET AL., LEUKEMIA, vol. 32, no. 3, March 2018 (2018-03-01), pages 843 - 846
WOOD ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 204, 2020
ZHANGBRAUN, INTERNATIONAL IMMUNOLOGY, vol. 26, 2014, pages 407 - 415

Also Published As

Publication number Publication date
BR112023021125A2 (pt) 2023-12-12
PE20242078A1 (es) 2024-10-18
EP4326259A1 (en) 2024-02-28
WO2022223543A1 (en) 2022-10-27
AU2022262199A1 (en) 2023-09-21
US20240207228A1 (en) 2024-06-27
CL2023002894A1 (es) 2024-03-15
JP2024515100A (ja) 2024-04-04
AR125356A1 (es) 2023-07-12
TW202308609A (zh) 2023-03-01
KR20230172001A (ko) 2023-12-21
IL307649A (en) 2023-12-01
CO2023013780A2 (es) 2023-11-10
CN117177745A (zh) 2023-12-05
MX2023012030A (es) 2023-10-24
CA3213275A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
JP7014731B2 (ja) 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
US10335494B2 (en) Combination of aurora kinase inhibitors and anti-CD30 antibodies
CN120285177A (zh) Hdac抑制剂和pd-1抑制剂的组合疗法
AU2017246460A1 (en) Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
CA2803675A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
BR112016014481B1 (pt) Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
CA2909625A1 (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
JP2025185043A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
US20250241913A1 (en) Combination therapies based on pd-1 inhibitors and sik3 inhibitors
IT202100009926A1 (it) Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
RU2849370C1 (ru) Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака
EA050310B1 (ru) Комбинация, содержащая специфический ингибитор hdac6 и по меньшей мере одно антитело к ctla4
KR20250126803A (ko) 일시적 수용체 전위 바닐로이드 6 억제제
JP2022540317A (ja) Ｈｓｐ９０結合コンジュゲートおよびその併用療法
JP2021525766A (ja) 併用療法